New bladder cancer therapy targets tumors with precision
NCT ID NCT05519241
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This early-stage trial tests a new drug delivery system for non-muscle-invasive bladder cancer that has not responded to standard BCG therapy. The drug, called PPM, uses tiny particles to deliver chemotherapy directly to cancer cells in the bladder. Up to 29 participants will receive the treatment to find the safest dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
RECRUITINGBoston, Massachusetts, 02130-4817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.